Group 1 - The core point of the article is that Yipinhong (300723.SZ) has received approval from the National Medical Products Administration for the drug registration certificate of Clindamycin Palmitate Granules, indicating a significant development for the company [1] - The approved indication for Clindamycin is for serious infections caused by sensitive anaerobic bacteria, as well as infections caused by sensitive strains of Streptococcus, Pneumococcus, and Staphylococcus, specifically for patients allergic to penicillin or deemed unsuitable for penicillin use by a physician [1] - The product's instruction clearly includes dosage and administration guidelines for children, highlighting its applicability in pediatric medicine [1] Group 2 - Clindamycin functions as an antibacterial drug by inhibiting bacterial protein synthesis through binding to the 23S rRNA of the 50S ribosomal subunit [1]

Core Viewpoint - The company Yipinhong (300723.SZ) has received approval from the National Medical Products Administration for the drug registration certificate of Clindamycin Palmitate Granules, indicating a significant advancement in its product offerings [1] Company Summary - Yipinhong's wholly-owned subsidiary, Guangzhou Yipinhong Pharmaceutical Co., Ltd., has been granted the drug registration certificate for Clindamycin Palmitate Granules [1] - Clindamycin is indicated for severe infections caused by sensitive anaerobic bacteria and is suitable for patients allergic to penicillin or those deemed unsuitable for penicillin by a physician [1]

一品红（300723）(300723.SZ)公告，公司全资子公司广州一品红制药有限公司于近日收到国家药品监 督管理局核准签发的关于盐酸克林霉素棕榈酸酯颗粒的《药品注册证书》。克林霉素适用于由敏感厌氧 菌引起的严重感染。克林霉素适用于由链球菌、肺炎球菌和葡萄球菌等敏感菌株引起的严重感染，但仅 适用于对青霉素过敏的患者或经医生判断不宜使用青霉素的患者。 ...

本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流，一品红药业集团股份有限公司（以下简 称"公司"）将参加由广东证监局、广东上市公司协会与深圳市全景网络有限公 司联合举办的"向新提质 价值领航 2025 年广东辖区上市公司投资者网上集体 接待日活动"，现将相关事项公告如下： 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （http://rs.p5w.net），或关注微信公众号：全景财经，或下载全景路演 APP,参 与本次互动交流，活动时间为 2025 年 9 月 19 日（周五）15:30-16:30。 届时公司董事长兼总经理李捍雄先生、副总经理兼董事会秘书张明渊先生以 及财务总监张辉星先生将在线就 2025 年半年度业绩、发展战略、经营状况等投 资者关心的问题，与投资者进行沟通与交流，欢迎广大投资者踊跃参与！ 特此公告！ 一品红药业集团股份有限公司 证券代码：300723 证券简称：一品红 公告编号：2025-059 一品红药业集团股份有限公司 关于参加 2025 年广东辖区上市公司投资者 网上集体接待日活动的公 ...

证券代码：300723 证券简称：一品红 公告编号：2025-060 一品红药业集团股份有限公司 剂 型：颗粒剂 关于全资子公司获得盐酸克林霉素棕榈酸酯颗粒注册证书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一品红药业集团股份有限公司（以下简称"公司"）全资子公司广州一品红 制药有限公司于近日收到国家药品监督管理局核准签发的关于盐酸克林霉素棕 榈酸酯颗粒的《药品注册证书》，现将有关事项公告如下： 一、药品注册证书主要信息 药品通用名称：盐酸克林霉素棕榈酸酯颗粒 英文名/拉丁名：Clindamycin Palmitate Hydrochloride Granules 主要成份：盐酸克林霉素棕榈酸酯 注册分类：化学药品 3 类 规 格：1.5g（按 C18H33ClN2O5S 计） 上市许可持有人地址：广州市经济技术开发区东区东博路 6 号 药品注册标准编号：YBH21752025 药品有效期：48 个月 申请事项：药品注册（境内生产） 包装规格： 1 瓶/盒 处方药/非处方药：处方药 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品 ...

Core Viewpoint - The company has received approval from the National Medical Products Administration for the drug registration certificate of Clindamycin Palmitate Granules, indicating a significant advancement in its pharmaceutical offerings [1] Group 1: Product Approval - The full subsidiary of the company, Guangzhou Yipinhong Pharmaceutical Co., Ltd., has recently obtained the drug registration certificate for Clindamycin Palmitate Granules [1] - Clindamycin is indicated for severe infections caused by sensitive anaerobic bacteria, as well as infections caused by sensitive strains of Streptococcus, Pneumococcus, and Staphylococcus [1] - The product is specifically indicated for patients who are allergic to penicillin or those deemed unsuitable for penicillin by a physician, with clear dosage instructions for pediatric use included in the product's labeling [1]

Investment Rating - The report maintains a "Recommended" investment rating for the pharmaceutical industry as of September 15, 2025 [1] Core Insights - The trend of Chinese innovative drugs going overseas continues, with a focus on selective opportunities. The report highlights that the global pharmaceutical transaction volume reached 456 deals in the first half of 2025, a 32% year-on-year increase, with upfront payments totaling $11.8 billion, a 136% surge, and total transaction value hitting $130.4 billion, up 58% year-on-year [2] - The report emphasizes the promising clinical data from Chinese innovative drugs presented at the World Lung Cancer Conference, particularly in the ADC (Antibody-Drug Conjugate) field, showcasing significant efficacy advantages [3] - The report discusses the potential of small nucleic acid drugs and innovative delivery systems, indicating new market opportunities arising from strategic collaborations between Chinese companies and multinational corporations [4] - The CXO (Contract Research Organization) sector is expected to gradually recover, with a notable increase in orders anticipated in the third quarter of 2025, driven by improved innovation environments and funding from license-out transactions [5] - The 2025 medical insurance negotiation and commercial insurance innovative drug directory work has commenced, with a focus on orphan drugs and breakthrough treatment varieties [6] Summary by Sections 1. Pharmaceutical Market Tracking - The pharmaceutical industry underperformed the CSI 300 index by 1.75% in the past week, with a recent one-month increase of 3.32%, lagging behind the CSI 300 by 5.81% [22][26] - The medical device sector showed the highest weekly increase of 2.23%, while the chemical pharmaceutical sector experienced a decline of 2.57% [31] 2. Pharmaceutical Sector Trends and Valuation - The pharmaceutical industry index's current PE (TTM) stands at 40.60, above the five-year historical average of 31.60 [46] - The report notes that the pharmaceutical sector has shown a 15.06% increase over the past three months, outperforming the CSI 300 by 16.11% [43] 3. Recent Research Achievements - The report outlines recent research achievements by the Huaxin pharmaceutical team, including various in-depth and commentary reports on innovative drug developments and market trends [50] 4. Recent Industry Policies and News - The report details recent policy updates from the National Healthcare Security Administration regarding the 2025 drug directory adjustments and the approval of new drug applications [52][55]

Core Viewpoint - The company Yipinhong stated on September 10 that as of August 31, 2025, the total number of shareholders is expected to be 21,360 [2] Company Summary - Yipinhong has engaged with investors through an interactive platform, providing insights into its shareholder structure [2] - The projected total number of shareholders indicates a stable or growing interest in the company, which may reflect positively on its market position [2]

Market Overview - On September 10, the chemical pharmaceutical sector declined by 1.15%, with Yipinhong leading the drop [1] - The Shanghai Composite Index closed at 3812.22, up 0.13%, while the Shenzhen Component Index closed at 12557.68, up 0.38% [1] Stock Performance - Notable gainers in the chemical pharmaceutical sector included: - Tonghua Golden Horse (000766) with a closing price of 25.03, up 4.42% and a trading volume of 439,300 shares, totaling 1.084 billion yuan [1] - ST Suwu (600200) closed at 66.0, up 4.21% with a trading volume of 358,500 shares [1] - Yiming Pharmaceutical (002826) closed at 19.97, up 3.90% with a trading volume of 104,000 shares [1] - Major decliners included: - Yipinhong (300723) closed at 61.42, down 10.41% with a trading volume of 220,400 shares, totaling 136.7 million yuan [2] - Mengke Pharmaceutical (688373) closed at 7.27, down 7.03% with a trading volume of 264,900 shares [2] - Baile Tianheng (688506) closed at 343.01, down 5.30% with a trading volume of 29,300 shares [2] Capital Flow - The chemical pharmaceutical sector experienced a net outflow of 2.552 billion yuan from institutional investors, while retail investors saw a net inflow of 1.816 billion yuan [2][3] - Key stocks with significant capital flow included: - Huadong Medicine (000963) had a net inflow of 62.886 million yuan from institutional investors [3] - Kelong Pharmaceutical (002422) saw a net inflow of 32.547 million yuan from institutional investors [3] - Huangshan Jiaohuan (002817) had a net inflow of 14.7405 million yuan from institutional investors [3]

Group 1 - The core viewpoint of the news is that Yipinhong Pharmaceutical Group Co., Ltd. has shown a significant stock price increase of 5.23%, reaching 70.19 CNY per share, with a total market capitalization of 31.704 billion CNY [1] - Yipinhong's main business includes the research, production, and sales of its own pharmaceuticals, as well as the sales of agent pharmaceuticals, with revenue composition being 61.12% from children's medicine, 22.71% from chronic disease medicine, and 16.17% from other products [1] Group 2 - According to fund data, Nord Fund has a significant holding in Yipinhong, with the Nord Small and Mid-Cap Mixed Fund (570006) holding 27,000 shares, accounting for 4.49% of the fund's net value, ranking as the tenth largest holding [2] - The Nord Small and Mid-Cap Mixed Fund has achieved a year-to-date return of 52.57%, ranking 541 out of 8248 in its category, and a one-year return of 53.23%, ranking 2182 out of 8051 [2] Group 3 - The fund manager of the Nord Small and Mid-Cap Mixed Fund is Zhu Mingrui, who has been in the position for 3 years and 68 days, with the fund's total asset size being 70.9838 million CNY [3] - During Zhu Mingrui's tenure, the best fund return was 43.58%, while the worst return was -6.35% [3]